Filing Details
- Accession Number:
- 0000950170-24-081628
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-07-03 17:13:34
- Reporting Period:
- 2024-07-01
- Accepted Time:
- 2024-07-03 17:13:34
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1088856 | Corcept Therapeutics Inc | CORT | Pharmaceutical Preparations (2834) | 770487658 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1879013 | William Guyer | C/O Corcept Therapeutics Incorporated 149 Commonwealth Drive Menlo Park CA 94025 | Chief Development Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-07-01 | 10,000 | $21.65 | 16,039 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-07-01 | 10,000 | $32.49 | 6,039 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock option (right to buy) | Disposition | 2024-07-01 | 10,000 | $0.00 | 10,000 | $21.65 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
490,000 | 2031-09-01 | No | 4 | M | Direct |
Footnotes
- Includes 478 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023 and 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction.
- Shares subject to the stock option vested and became exercisable with respect to 25% of the shares on the first anniversary of August 16, 2021 (the "Vesting Commencement Date") with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.